Recursion Pharmaceuticals Analyst Ratings
Jefferies Initiates Recursion Pharmaceuticals at Hold With $8 Price Target
Recursion Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Applied Therapeutics (APLT), Carisma Therapeutics (CARM) and Recursion Pharmaceuticals (RXRX)
Recursion Pharmaceuticals: A Buy Rating With Growth and Innovation on the Horizon
Recursion Pharmaceuticals Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Recursion Pharmaceuticals (RXRX)
Recursion Pharmaceuticals Analyst Ratings
Recursion Pharmaceuticals Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Beam Therapeutics (BEAM), ACADIA Pharmaceuticals (ACAD) and Recursion Pharmaceuticals (RXRX)
Recursion Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Recursion Pharmaceuticals (RXRX) and Arcutis Biotherapeutics (ARQT)
Recursion Pharmaceuticals Analyst Ratings
Recursion Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Recursion Pharmaceuticals (RXRX), Edgewise Therapeutics (EWTX) and Eledon Pharmaceuticals (ELDN)
JP Morgan Maintains Neutral on Recursion Pharmaceuticals, Lowers Price Target to $10
Recursion Pharmaceuticals Analyst Ratings
Needham Adjusts Recursion Pharmaceuticals Price Target to $15 From $17, Maintains Buy Rating
Needham Maintains Buy on Recursion Pharmaceuticals, Lowers Price Target to $15
Recursion Pharmaceuticals Analyst Ratings